Carbaglu monitoring study for suspected NAGS deficiency
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study follows people who have (or might have) NAGS deficiency and who are taking Carbaglu to treat it. The goal is to better track safety and health outcomes over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of NAGS deficiency or a strong suspicion of it
- You are currently taking Carbaglu (Carbaglu intake) for NAGS deficiency
- You are already enrolled in the RDCRN Longitudinal Study of Urea Cycle Disorders (protocol #5101)
- Your high ammonia (if it happens) is not from other urea cycle disorders
- You do not have certain other conditions such as primary liver disease or major inherited metabolism disorders
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This observational study looks at how Carbaglu® is used and how well it works for people with methylmalonic acidemia (MMA) or propionic acidemia (PA). It may help doctors understand real-world care for adults and children living with these conditions.
This study looks at liver tissue (under a microscope) in people with urea cycle disorders to better understand liver changes from the condition. It may help clinicians learn what to watch for and how to manage liver health, especially around liver biopsy or transplant.
This trial studies blood and other measurable signs (biomarkers) that may reflect brain injury after certain inherited metabolic conditions. Results may help doctors better detect and understand brain effects from these illnesses, especially episodes that affect the brain.
This study tests an oral supplement called N-acetylglucosamine (a natural sugar) to see if it can help control Crohn's disease. It involves taking the supplement and attending follow-up visits, including some genetic testing.
This trial tests a new medicine called LNP.UCD.ABE that aims to fix a specific genetic change causing a severe urea cycle disorder. It uses a technique called base editing to correct the gene mutation, which may help your body break down ammonia better.
This study follows people with certain inherited metabolic conditions (like GM1 or GM2 gangliosidosis, sialidosis, or galactosialidosis) to learn more about how these diseases progress over time. Participating may help researchers understand the conditions better, which could improve future care.
Hear when a new N-acetylglutamate Synthase (NAGS) Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.